Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 848 of 6351
-
New drug combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutatio…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New epilepsy drug XEN1101 tested for long-term seizure control
Disease control By invitation onlyThis study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years.
Phase 3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo aims to control aggressive bone cancer in young patients
Disease control Recruiting nowThis phase II trial studies the effect of atezolizumab and cabozantinib in treating adolescents and young adults with osteosarcoma that has come back (recurrent) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New quadrivalent flu vaccine shows promise for kids under 3
Vaccine CompletedThis is a Phase III Randomized Clinical Trial, blind, multicenter, with active controls, to evaluate the immunogenicity and safety of the Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan, in two dose scheme (0.25ml and 0.50ml), in infants and chi…
Phase 3 • Sponsor: Butantan Institute • Aim: Vaccine
Last updated Jun 26, 2026 19:13 UTC
-
New CAR-T therapy targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.
Phase 1 • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug combo targets tough breast cancer subtype in phase 3 trial
Disease control Recruiting nowThe study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune suppressed (BLIS) subtype of triple-negative breast cancer (TNBC) in the first-line teatment of unresecta…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can we spot cancer before it starts? a massive study aims to find out
Knowledge-focused Recruiting nowThis research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
New drug cocktail aims to fight Hard-to-Treat liver cancers
Disease control OngoingGEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
A common antibiotic may help Crohn's patients get more out of biologic therapy
Disease control Recruiting nowThis is a randomized placebo-controlled trial in Crohn's disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity
Phase 2 • Sponsor: Rambam Health Care Campus • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedThis is a phase II prospective study to evaluate the safety and efficacy of Tislelizumab monotherapy or combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma.
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New DNA blood test could speed up heart infection diagnosis
Diagnosis OngoingInfective Endocarditis is an infection, usually a bacterium, which attacks the heart and can cause valves to leak and produces a bacterial mass which can break off from the valves and block the blood supply to important organs. We are very keen to improve the treatment of this d…
Sponsor: Queen Mary University of London • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
A UV photo and a cheek swab may be the keys to stopping sunburn before it starts
Prevention OngoingThe proposed study is a Multiphase Optimization Strategy (MOST) that uses factorial experiments to evaluate individual and combined effects of intervention components to improve intervention efficiency. The study team anticipates enrolling a total of 528 undergraduate students (\…
Phase 3 • Sponsor: University of Utah • Aim: Prevention
Last updated Jul 29, 2026 00:00 UTC
-
New triple inhaler could help teens with Hard-to-Control asthma
Disease control Recruiting nowThe primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Can MRI outperform ultrasound for breast cancer screening in dense breasts?
Diagnosis OngoingThe goal of this randomized clinical trial is to compare diagnostic results of secondary breast cancer surveillance using breast ultrasound abbreviated MRI and full protocol MRI.
Sponsor: Samsung Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
Disease control OngoingThis is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
Phase 1 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Lung cancer vaccine combo shows promise in early trial
Disease control OngoingThis study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New way to deliver c. diff treatment: through a colonoscopy
Disease control CompletedThis trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy. More specifically, the purpose of this trial is to explore the safety and clinical effectiveness of RBX2660 when delivered by colonoscopy to adu…
Phase 3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could lifestyle changes protect hearts in PTSD?
Disease control Recruiting nowThis project examines the impact of a healthy lifestyle intervention, specifically designed for adults with posttraumatic stress and identified cardiovascular risks.
Sponsor: Nova Southeastern University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Weight loss drug showdown: which works better?
Disease control CompletedThe main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThe trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC